Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.

Abstract: In certain embodiments, vision defect information may be generated via a dynamic eye-characteristic-based fixation point. In some embodiments, a first stimulus may be displayed at a first location on a user interface based on a fixation point for a visual test presentation. The fixation point for the visual test presentation may be adjusted during the visual test presentation based on eye characteristic information related to a user. As an example, the eye characteristic information may indicate a characteristic of an eye of the user that occurred during the visual test presentation. A second stimulus may be displayed during the visual test presentation at a second interface location on the user interface based on the adjusted fixation point for the visual test presentation. Vision defect information associated with the user may be generated based on feedback information indicating feedback related to the first stimulus and feedback related to the second stimulus.

Abstract: In certain embodiments, enhancement of a field of view of a user may be facilitated via one or more dynamic display portions. In some embodiments, one or more changes related to one or more eyes of a user may be monitored. Based on the monitoring, one or more positions of one or more transparent display portions of wearable device may be adjusted, where the transparent display portions enable the user to see through the wearable device. A live video stream representing an environment of the user may be obtained via the wearable device. A modified video stream derived from the live video stream may be displayed on one or more other display portions of the wearable device.

Abstract: Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.

Abstract: The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.

Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.

Abstract: In certain embodiments, enhancement of a vision of a user may be facilitated. In some embodiments, a visual test presentation including a set of stimuli may be provided to a user. Feedback related to the set of stimuli may be obtained during the visual test presentation. The feedback may be provided to a prediction model, and the prediction model may be configured based on the feedback. Subsequent to the configuring of the prediction model, live video stream data, eye characteristic information, or other information may be provided to the prediction model to obtain a set of modification parameters. A modified version of the live video stream data may be generated and displayed to the user based on the live video stream and the set of modification parameters.

Abstract: The subject invention provides novel apparatuses and methods for assessing the structure and function of photoreceptors in retina. In a specific embodiment, the assessment is accomplished by imaging rhodopsin, pigmented protein responsible for initiating vision acquisition of the eye, in living subjects. Advantageously, the technologies provided herein can be used for clinical evaluation of retinal photoreceptors for diagnosis, disease staging and follow-up, and outcome measurement for clinical trials of retinal degenerative disorders, including, for example, hereditary retinal degeneration and age-related macular degeneration.

Abstract: In certain embodiments, enhancement of a field of view of a user may be facilitated via one or more dynamic display portions. In some embodiments, one or more changes related to one or more eyes of a user may be monitored. Based on the monitoring, one or more positions of one or more transparent display portions of wearable device may be adjusted, where the transparent display portions enable the user to see through the wearable device. A live video stream representing an environment of the user may be obtained via the wearable device. A modified video stream derived from the live video stream may be displayed on one or more other display portions of the wearable device.

Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.

Abstract: A method of predicting a disease or condition of a cornea or an anterior segment of an eye includes inputting input data into an AI model, processing the input data, and generating a set of scores and outputting a prediction. The input data may be representative of a cornea or anterior segment of an eye. Processing the input data may include processing the data through the plurality of convolutional layers, the fully connected layer, and the output layer. Each score of the set of scores may be generated by a corresponding node in the output layer. The output prediction may be related to the cornea or anterior segment of the eye represented by the input data processed through the AI model. The prediction may be determined by at least one score of the set of scores.

Abstract: Disclosed herein are methods for treating/and or preventing diabetes using a specific inhibitor of SMAD7 expression or function. Also disclosed are methods of promoting organ and/or cell, e.g., pancreatic islet cell, survival after transplantation using a specific inhibitor of SMAD7 expression or function.

Abstract: A water body drifter device for tracking movement of a fluid is disclosed. The drifter may include a floater assembly having a toroid shaped buoy fixedly connected to a floater head disposed interiorly to the toroid shaped buoy, the floater head having a recess and a cap sealably attached to the recess for housing a network-enabled controller. The drifter may also include one or more sensors mounted to the floater assembly to capture physical, chemical or biological data from the water body and/or from the environment around the water body, a drogue formed of a plurality of blades each spaced from one another, and a flexible connector attached to the floater assembly at one end and the drogue at another end. The floater assembly, the drogue, and the flexible connector may each be formed of one or more biodegradable materials.

Abstract: In certain embodiments, enhancement of a field of view of a user may be facilitated via one or more dynamic display portions. In some embodiments, one or more changes related to one or more eyes of a user may be monitored. Based on the monitoring, one or more positions of one or more transparent display portions of a screen of wearable device may be adjusted, where the transparent display portions enable the user to see through the screen of the wearable device. A live video stream representing an environment of the user may be obtained via the wearable device. An enhanced video stream derived from the live video stream may be displayed on one or more other display portions of the screen of the wearable device.

Abstract: In certain embodiments, live image data modifications may be facilitated for dynamic vision defects. In some embodiments, one or more eyes of a user may be monitored while a set of stimuli are displayed to the user. Feedback related to the set of stimuli may be obtained, where the feedback indicates (i) whether or how the user sees one or more stimuli of the set and (ii) one or more characteristics related to the eyes that occurred when such stimuli are displayed. A set of modification profiles associated with the user may be generated based on the feedback, where each modification profile of the set (i) is associated with eye-related characteristics and (ii) includes modification parameters to be applied to an image to modify the image for the user when eye-related characteristics of the user matches the associated eye-related characteristics.

Abstract: Devices for testing, identifying, and compensating for ocular pathologies affecting the vision of a patient are provided in the form of digital therapeutic corrective spectacles that provided personalized, customized visual field corrected/enhancement. The devices include wearable spectacles with one or more digital monitors that are used to recreate an entire visual field as a digitized corrected image or that include custom-reality glasses that can be used to overlay a visual scene with generated image to correct or enhance the visual field of the subject.

Abstract: In certain embodiments, enhancement of a vision of a user may be facilitated. In some embodiments, a visual test presentation including a set of stimuli may be provided to a user. Feedback related to the set of stimuli may be obtained during the visual test presentation. The feedback may be provided to a prediction model, and the prediction model may be configured based on the feedback. Subsequent to the configuring of the prediction model, live video stream data, eye characteristic information, or other information may be provided to the prediction model to obtain a set of modification parameters. An enhanced image may be generated and displayed to the user based on the live video stream and the set of modification parameters.

Abstract: The disclosure provides an ophthalmic formulation comprising a bromodomain inhibitor, a polar aprotic solvent (e.g., dimethyl sulfoxide (DMSO)), polysorbate, salt, and Captisol, as well as a method of treating or preventing ophthalmic inflammation in a subject in need thereof comprising locally administering the formulation to the eye of the subject.

Abstract: Techniques for improved diagnosis, treatment, and monitoring of corneal pathologies use enhanced mapping of the cornea or corneal regions, to develop three-dimensional mapping of corneal thickness, while retaining particular corneal micro-layer thickness data. Anterior and posterior surface identifications, along with surface apex determinations, are used for registration of segmentation of these micro-layers. 3D heat maps and bull's-eye maps are generated from resulting thickness date. The maps provided enhanced evaluation and diagnosis of a corneal pathologies, such as keratoconus, pellucid marginal degeneration, post-refractive surgery ectasia, keratoglobus, corneal transplant rejection and corneal transplant failed grafts, Fuchs dystrophy, corneal limbal stem cell deficiency, dry eye syndrome, and post-corneal collagen crosslinking evaluation.

Abstract: In certain embodiments, live image data modifications may be facilitated for dynamic vision defects. In some embodiments, one or more eyes of a user may be monitored while a set of stimuli are displayed to the user. Feedback related to the set of stimuli may be obtained, where the feedback indicates (i) whether or how the user sees one or more stimuli of the set and (ii) one or more characteristics related to the eyes that occurred when such stimuli are displayed. A set of modification profiles associated with the user may be generated based on the feedback, where each modification profile of the set (i) is associated with eye-related characteristics and (ii) includes modification parameters to be applied to an image to modify the image for the user when eye-related characteristics of the user matches the associated eye-related characteristics.